Geode Capital Management
ANIX icon

Geode Capital Management’s Anixa Biosciences ANIX Stock Holding History

Geode Capital Management’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$941K Buy
364,731
+13,816
+4% +$40.9K ﹤0.01% 3373
2025
Q4 		$1.1M Buy
350,915
+7,271
+2% +$29.8K ﹤0.01% 3347
2025
Q3 		$1.13M Buy
343,644
+808
+0.2% +$2.56K ﹤0.01% 3346
2025
Q2 		$1.13M Buy
342,836
+2,571
+0.8% +$7.35K ﹤0.01% 3286
2025
Q1 		$973K Buy
340,265
+10,888
+3% +$31.1K ﹤0.01% 3312
2024
Q4 		$764K Buy
329,377
+599
+0.2% +$1.86K ﹤0.01% 3459
2024
Q3 		$1.04M Sell
328,778
-1,797
-0.5% -$5.53K ﹤0.01% 3345
2024
Q2 		$731K Buy
330,575
+10,427
+3% +$29.6K ﹤0.01% 3424
2024
Q1 		$999K Buy
320,148
+7,676
+2% +$30.6K ﹤0.01% 3358
2023
Q4 		$1.21M Buy
312,472
+12,826
+4% +$43.3K ﹤0.01% 3279
2023
Q3 		$980K Sell
299,646
-3,372
-1% -$11.8K ﹤0.01% 3329
2023
Q2 		$970K Buy
303,018
+28,729
+10% +$111K ﹤0.01% 3373
2023
Q1 		$1.18M Hold
274,289
– – ﹤0.01% 3268
2022
Q4 		$1.17M Buy
274,289
+3,626
+1% +$17.4K ﹤0.01% 3281
2022
Q3 		$1.33M Buy
270,663
+660
+0.2% +$2.67K ﹤0.01% 3251
2022
Q2 		$826K Buy
270,003
+779
+0.3% +$2.46K ﹤0.01% 3511
2022
Q1 		$737K Buy
269,224
+5,273
+2% +$15.5K ﹤0.01% 3754
2021
Q4 		$783K Hold
263,951
– – ﹤0.01% 3830
2021
Q3 		$1.26M Buy
263,951
+50,147
+23% +$226K ﹤0.01% 3566
2021
Q2 		$829K Buy
213,804
+44,846
+27% +$191K ﹤0.01% 3699
2021
Q1 		$790K Buy
168,958
+57,153
+51% +$273K ﹤0.01% 3653
2020
Q4 		$343K Buy
111,805
+9,318
+9% +$23.4K ﹤0.01% 3717
2020
Q3 		$249K Hold
102,487
– – ﹤0.01% 3647
2020
Q2 		$313K Hold
102,487
– – ﹤0.01% 3528
2020
Q1 		$162K Hold
102,487
– – ﹤0.01% 3617
2019
Q4 		$336K Hold
102,487
– – ﹤0.01% 3635
2019
Q3 		$409K Hold
102,487
– – ﹤0.01% 3539
2019
Q2 		$372K Hold
102,487
– – ﹤0.01% 3573
2019
Q1 		$463K Buy
102,487
+3,082
+3% +$14.7K ﹤0.01% 3462
2018
Q4 		$391K Buy
+99,405
New +$427K ﹤0.01% 3460
2018
Q3 		– Sell
-87,602
Closed -$265K – 4124
2018
Q2 		$265K Hold
87,602
– – ﹤0.01% 3644
2018
Q1 		$336K Hold
87,602
– – ﹤0.01% 3528
2017
Q4 		$206K Buy
87,602
+53,251
+155% +$138K ﹤0.01% 3665
2017
Q3 		$90K Hold
34,351
– – ﹤0.01% 3842
2017
Q2 		$39K Hold
34,351
– – ﹤0.01% 3989
2017
Q1 		$101K Hold
34,351
– – ﹤0.01% 3826
2016
Q4 		$185K Hold
34,351
– – ﹤0.01% 3642
2016
Q3 		$133K Hold
34,351
– – ﹤0.01% 3730
2016
Q2 		$107K Hold
34,351
– – ﹤0.01% 3781
2016
Q1 		$101 Hold
34,351
– – ﹤0.01% 3828
2015
Q4 		$103K Hold
34,351
– – ﹤0.01% 3876
2015
Q3 		$162K Buy
+34,351
New +$160K ﹤0.01% 3756

Other funds holding ANIX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management's ANIX Position: Q1 2026 in Review

Geode Capital Management increased its Anixa Biosciences (ANIX) stake by 3.9% in Q1 2026, buying an estimated $40.9K and bringing the position to 364,731 shares worth $941K. The position accounts for ﹤0.01% of the portfolio, ranked #3373.

Geode Capital Management first reported a position in ANIX in Q3 2015 and has held it in 42 quarters since. The position peaked at $1.33M in Q3 2022. 60 funds tracked by Wall St. Rank hold ANIX as of Q1 2026.

  • Geode Capital Management held 364,731 shares of Anixa Biosciences worth $941K as of Q1 2026.
  • Geode Capital Management bought 13,816 Anixa Biosciences shares in Q1 2026, an estimated $40.9K.
  • Anixa Biosciences made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3373 holding.
  • Geode Capital Management first reported a position in Anixa Biosciences in Q3 2015 and has held it in 42 quarters since.
  • Geode Capital Management's Anixa Biosciences position peaked at $1.33M in Q3 2022.
  • 60 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.